ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Pfizer is likely to show GSK significant competition
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
The company has reported total income of Rs. 604.02 crores during the period ended March 31, 2023
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Proposed combination enhances Pfizer’s position as a leading company in oncology
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Subscribe To Our Newsletter & Stay Updated
